164 related articles for article (PubMed ID: 14632470)
21. Refining the multiple protein structure pharmacophore method: consistency across three independent HIV-1 protease models.
Meagher KL; Lerner MG; Carlson HA
J Med Chem; 2006 Jun; 49(12):3478-84. PubMed ID: 16759090
[TBL] [Abstract][Full Text] [Related]
22. Fingerprint-based clustering applied to define a QSAR model use radius.
Sprous DG
J Mol Graph Model; 2008 Sep; 27(2):225-32. PubMed ID: 18556228
[TBL] [Abstract][Full Text] [Related]
23. Exploring QSARs for inhibitory activity of non-peptide HIV-1 protease inhibitors by GA-PLS and GA-SVM.
Deeb O; Goodarzi M
Chem Biol Drug Des; 2010 May; 75(5):506-14. PubMed ID: 20486937
[TBL] [Abstract][Full Text] [Related]
24. Quantitative structure-activity relationship by CoMFA for cyclic urea and nonpeptide-cyclic cyanoguanidine derivatives on wild type and mutant HIV-1 protease.
Avram S; Bologa C; Flonta ML
J Mol Model; 2005 Mar; 11(2):105-15. PubMed ID: 15714296
[TBL] [Abstract][Full Text] [Related]
25. Comparing the quality and predictiveness between 3D QSAR models obtained from manual and automated alignment.
Tervo AJ; Nyrönen TH; Rönkkö T; Poso A
J Chem Inf Comput Sci; 2004; 44(3):807-16. PubMed ID: 15154745
[TBL] [Abstract][Full Text] [Related]
26. InChI-based optimal descriptors: QSAR analysis of fullerene[C60]-based HIV-1 PR inhibitors by correlation balance.
Toropov AA; Toropova AP; Benfenati E; Leszczynska D; Leszczynski J
Eur J Med Chem; 2010 Apr; 45(4):1387-94. PubMed ID: 20116899
[TBL] [Abstract][Full Text] [Related]
27. Constructing plasma protein binding model based on a combination of cluster analysis and 4D-fingerprint molecular similarity analyses.
Liu J; Yang L; Li Y; Pan D; Hopfinger AJ
Bioorg Med Chem; 2006 Feb; 14(3):611-21. PubMed ID: 16214346
[TBL] [Abstract][Full Text] [Related]
28. Cyclic HIV-1 protease inhibitors derived from mannitol: synthesis, inhibitory potencies, and computational predictions of binding affinities.
Hultén J; Bonham NM; Nillroth U; Hansson T; Zuccarello G; Bouzide A; Aqvist J; Classon B; Danielson UH; Karlén A; Kvarnström I; Samuelsson B; Hallberg A
J Med Chem; 1997 Mar; 40(6):885-97. PubMed ID: 9083477
[TBL] [Abstract][Full Text] [Related]
29. Computational design of new cyclic urea inhibitors for improved binding of HIV-1 aspartic protease.
Kotamarthi B; Bonin I; Benedetti F; Miertus S
Biochem Biophys Res Commun; 2000 Feb; 268(2):384-9. PubMed ID: 10679213
[TBL] [Abstract][Full Text] [Related]
30. A genetic algorithm optimized fuzzy neural network analysis of the affinity of inhibitors for HIV-1 protease.
Fabry-Asztalos L; Andonie R; Collar CJ; Abdul-Wahid S; Salim N
Bioorg Med Chem; 2008 Mar; 16(6):2903-11. PubMed ID: 18194868
[TBL] [Abstract][Full Text] [Related]
31. Rational design and 3D-pharmacophore mapping of 5'-thiourea-substituted alpha-thymidine analogues as mycobacterial TMPK inhibitors.
Andrade CH; Pasqualoto KF; Ferreira EI; Hopfinger AJ
J Chem Inf Model; 2009 Apr; 49(4):1070-8. PubMed ID: 19296716
[TBL] [Abstract][Full Text] [Related]
32. 3D QSAR studies on protein tyrosine phosphatase 1B inhibitors: comparison of the quality and predictivity among 3D QSAR models obtained from different conformer-based alignments.
Pandey G; Saxena AK
J Chem Inf Model; 2006; 46(6):2579-90. PubMed ID: 17125198
[TBL] [Abstract][Full Text] [Related]
33. Binding affinity prediction of non-peptide inhibitors of HIV-1 protease using COMBINE model introduced from peptide inhibitors.
Nakamura S; Nakanishi I; Kitaura K
Bioorg Med Chem Lett; 2006 Dec; 16(24):6334-7. PubMed ID: 17027266
[TBL] [Abstract][Full Text] [Related]
34. Local and global quantitative structure-activity relationship modeling and prediction for the baseline toxicity.
Yuan H; Wang Y; Cheng Y
J Chem Inf Model; 2007; 47(1):159-69. PubMed ID: 17238261
[TBL] [Abstract][Full Text] [Related]
35. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
[TBL] [Abstract][Full Text] [Related]
36. Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.
Huang PP; Randolph JT; Klein LL; Vasavanonda S; Dekhtyar T; Stoll VS; Kempf DJ
Bioorg Med Chem Lett; 2004 Aug; 14(15):4075-8. PubMed ID: 15225729
[TBL] [Abstract][Full Text] [Related]
37. Validated predictive QSAR modeling of N-aryl-oxazolidinone-5-carboxamides for anti-HIV protease activity.
Halder AK; Jha T
Bioorg Med Chem Lett; 2010 Oct; 20(20):6082-7. PubMed ID: 20832304
[TBL] [Abstract][Full Text] [Related]
38. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties.
Frecer V; Berti F; Benedetti F; Miertus S
J Mol Graph Model; 2008 Oct; 27(3):376-87. PubMed ID: 18678515
[TBL] [Abstract][Full Text] [Related]
39. Insight into the structural requirements of urokinase-type plasminogen activator inhibitors based on 3D QSAR CoMFA/CoMSIA models.
Bhongade BA; Gadad AK
J Med Chem; 2006 Jan; 49(2):475-89. PubMed ID: 16420035
[TBL] [Abstract][Full Text] [Related]
40. Synthesis of novel cyclic urea based HIV-1 protease inhibitors.
Nugiel DA; Reese K
Drug Des Discov; 1995 Nov; 13(2):83-7. PubMed ID: 8872453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
